Literature DB >> 78009

Anti-acetylcholine receptor antibodies in D-penicillamine-associated myasthenia gravis.

A Vincent, J Newsom-Davis, V Martin.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 78009     DOI: 10.1016/s0140-6736(78)92481-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

Review 1.  Drug interactions with neuromuscular blockers.

Authors:  S Feldman; L Karalliedde
Journal:  Drug Saf       Date:  1996-10       Impact factor: 5.606

Review 2.  Myasthenia gravis: an autoimmune response against the acetylcholine receptor.

Authors:  Y M Graus; M H De Baets
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

Review 3.  Tissue-specific antibodies in myasthenia gravis.

Authors:  A Vincent
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1979

Review 4.  Pathogenesis and treatment of myasthenia gravis.

Authors:  G K Scadding; C W Havard
Journal:  Br Med J (Clin Res Ed)       Date:  1981-10-17

5.  Penicillamine-induced myasthenia in rheumatoid arthritis: its clinical and genetic features.

Authors:  J P Delamere; S Jobson; L P Mackintosh; L Wells; K W Walton
Journal:  Ann Rheum Dis       Date:  1983-10       Impact factor: 19.103

6.  Acetylcholine receptor antibody characteristics in myasthenia gravis. II. Patients with penicillamine-induced myasthenia or idiopathic myasthenia of recent onset.

Authors:  A Vincent; J Newsom-Davis
Journal:  Clin Exp Immunol       Date:  1982-08       Impact factor: 4.330

Review 7.  Pinnatoxins' Deleterious Effects on Cholinergic Networks: From Experimental Models to Human Health.

Authors:  Nicolas Delcourt; Emmeline Lagrange; Eric Abadie; Valérie Fessard; Jean-Marc Frémy; Jean-Paul Vernoux; Marie-Bénédicte Peyrat; Thomas Maignien; Nathalie Arnich; Jordi Molgó; César Mattei
Journal:  Mar Drugs       Date:  2019-07-20       Impact factor: 5.118

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.